After Pfizer's $14 billion proposed acquisition of Medivation, these biotech stocks could emerge as winners, if history is any guide. » Read More
By: Brian Price
Priscilla Hancock of JPMorgan Asset Management explains when she believes the Federal Reserve will hike interest rates. » Read More
The "Fast Money" traders share their first moves for the market open.
Jim Cramer is seeing signs that companies are buying back stocks as a message that they are undervalued.
Jim Cramer goes off the charts to find two stocks that could explode higher in the return of retail.
The furniture maker said it saw its quarterly same-store sales decline by 1.9 percent.
UBS analysts upgraded their rating of CF Industries and increased a 12-month price target, sending the company's shares higher.
Clovis Oncology shares shot up more than 26 percent Tuesday after the FDA accepted the company's new drug application.
Both Tesla Motors and SolarCity shares gave up their gains after Tesla announced new versions of its Model S and Model X.
Toll Brothers reported a rise in revenue for the fourth straight quarter, beating analysts' estimates.
As major averages continue to scale new highs, one Wall Street firm believes the stock market rally is getting overdone.
Gold mining stocks are having a great year so far, but one technical analyst urges investors to wait and see.
Cramer said he doesn't want to bet against J.M. Smucker CEO Mark Smucker after the company posted quarterly revenue that fell short.
One day after the second-lowest daily volume of the year, U.S. equities have been trading in a very tight range amid extremely low volatility.
The backdrop for the S&P's 15 percent rise is a market that is expecting a "one-and-wait" interest rate cycle, Todd Gordon says.
Jim Cramer isn't salivating about biotech acquisitions like everyone else. Instead, he says this group is the next fiery group to watch.
Some of the names on the move ahead of the open.
Jim Cramer analyzed the winners and losers in retail for the quarter and discovered an interesting trend.
Get the best of CNBC in your inbox